Opus Genetics, Inc.
NASDAQ:IRD · NASDAQ Global Market
+$0.13 today
Vol 0.76M · Avg 0.86M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:IRD · Revenue to Net Income
Key Ratios
Analysis
$12.0M of revenue converted into -$106.9M of net income for the selected period. Gross margin is 47.6% and net margin is -1072.5%, showing how much revenue survives after costs and taxes. EPS is $-1.31, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.2M +29.1% | $11.0M -42.3% | $19.0M -52.2% | $39.9M +6665.7% | $589.0K | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $14.2M +29.1% | $11.0M -42.3% | $19.0M -52.2% | $39.9M +6665.7% | $589.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $30.8M +14.8% | $26.9M +52.1% | $17.7M +23.0% | $14.4M -5.4% | $15.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $22.0M +20.7% | $18.2M +52.3% | $12.0M +64.5% | $7.3M -10.5% | $8.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $52.8M -27.7% | $73.1M +146.7% | $29.6M +36.9% | $21.6M -7.2% | $23.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $53.0K +430.0% | $10.0K +66.7% | $6.0K +50.0% | $4.0K +0.0% | $4.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$48.1M +16.4% | -$57.5M -477.1% | -$10.0M -154.7% | $18.2M +132.1% | -$56.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -338.6% +184.7pp | -523.3% -471.0pp | -52.3% -98.0pp | 45.7% +9670.0pp | -9624.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$38.6M +37.8% | -$62.1M -487.7% | -$10.6M -158.0% | $18.2M +180.3% | -$22.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -271.9% +292.8pp | -564.7% -509.3pp | -55.5% -101.2pp | 45.7% +3900.6pp | -3854.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.5M | $0 -100.0% | $1.3M +14655.6% | $9.0K +350.0% | $2.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$11.0M -342.0% | $4.5M +671.1% | $589.0K +2660.9% | -$23.0K +99.9% | -$34.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$49.6M +13.8% | -$57.5M -476.8% | -$10.0M -154.8% | $18.2M +132.1% | -$56.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -349.3% +174.1pp | -523.4% -471.0pp | -52.4% -98.0pp | 45.7% +9671.0pp | -9625.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 -100.0% | $12.0K -96.2% | $315.0K | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$49.6M +13.8% | -$57.5M -476.1% | -$10.0M -155.8% | $17.9M +131.6% | -$56.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -349.3% +174.1pp | -523.4% -471.0pp | -52.4% -97.3pp | 44.9% +9670.2pp | -9625.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +62.8% | -$2 -367.4% | -$0 -151.1% | $1 +123.6% | -$4 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +62.8% | -$2 -367.4% | -$0 -152.9% | $1 +122.8% | -$4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $622.2M +2229.1% | $26.7M +23.7% | $21.6M +8.3% | $19.9M +34.2% | $14.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $622.2M +2229.1% | $26.7M +23.7% | $21.6M +4.8% | $20.6M +38.7% | $14.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alector, Inc.
NASDAQ:ALEC
$169.87M
TuHURA Biosciences, Inc.
NASDAQ:HURA
$147.74M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$143.56M
Agenus Inc.
NASDAQ:AGEN
$137.42M
Seer, Inc.
NASDAQ:SEER
$94.57M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.95M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$55.20M
Instil Bio, Inc.
NASDAQ:TIL
$53.71M
VistaGen Therapeutics, Inc.
VTGN
$18.88M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does IRD generate?
Opus Genetics, Inc. (IRD) reported $14.20M of revenue in fiscal 2025.
Is IRD profitable?
Opus Genetics, Inc. (IRD) reported -$49,591,000.00 of net income, with a net margin of -349.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.